Biomea Fusion (BMEA) Expected to Announce Quarterly Earnings on Thursday

Biomea Fusion (NASDAQ:BMEA - Get Free Report) is projected to issue its Q1 2025 quarterly earnings data before the market opens on Thursday, May 1st. Analysts expect the company to announce earnings of ($0.90) per share for the quarter.

Biomea Fusion (NASDAQ:BMEA - Get Free Report) last posted its quarterly earnings results on Monday, March 31st. The company reported ($0.81) earnings per share for the quarter, beating the consensus estimate of ($1.00) by $0.19. On average, analysts expect Biomea Fusion to post $-4 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Biomea Fusion Stock Performance

BMEA stock traded down $0.04 during mid-day trading on Tuesday, hitting $2.20. The company had a trading volume of 376,057 shares, compared to its average volume of 907,582. Biomea Fusion has a 12 month low of $1.53 and a 12 month high of $13.43. The stock's fifty day moving average price is $2.33 and its two-hundred day moving average price is $4.80. The firm has a market cap of $82.66 million, a PE ratio of -0.55 and a beta of -0.07.

Wall Street Analyst Weigh In

Several research firms recently commented on BMEA. D. Boral Capital reiterated a "buy" rating and issued a $16.00 price objective on shares of Biomea Fusion in a research note on Wednesday, March 19th. Barclays dropped their price target on Biomea Fusion from $11.00 to $3.00 and set an "equal weight" rating on the stock in a research report on Wednesday, April 2nd. HC Wainwright reissued a "buy" rating and issued a $40.00 price objective on shares of Biomea Fusion in a report on Monday, March 31st. Finally, Oppenheimer set a $10.00 price objective on Biomea Fusion in a research note on Monday, March 24th. Two research analysts have rated the stock with a hold rating, nine have given a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, Biomea Fusion has an average rating of "Buy" and an average price target of $23.91.

Biomea Fusion Company Profile

Biomea Fusion, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes.